Australian Government
Australian Digital Health Agency

Dear Industry Colleagues

I am writing to reaffirm the Australian Digital Health Agency's expectations regarding the transition to contemporary electronic prescribing conformance requirements, and to emphasise that the 30 September 2026 deadline remains final and will not be extended.

As previously communicated in March 2025, the phase-out of legacy Conformance Profiles introduced during the COVID-19 response is a critical step in maintaining a safe, secure and interoperable national electronic prescribing ecosystem. This transition ensures greater consistency across systems and supports the ongoing safety of consumers and healthcare providers.

Following extensive consultation with industry, the Agency extended the sunset timeframe for Electronic Prescribing - Conformance Profile v2.3 from 24 November 2023 to 30 June 2025, and then finally 30 September 2026 to support industry transition challenges. With this date now approaching, we are reinforcing that it remains fixed and will not be extended, and all vendors should be well progressed in their transition activities.

To remain on the Electronic Prescribing Conformance Register, and to support the lawful issuing and dispensing of prescriptions, products must meet the following requirements and timeframes:

- By **30 September 2026**, all electronic prescribing (EP) products must be registered on the EP Conformance Register as conformant to Electronic Prescribing – Conformance Profile v3.0.1
- Developers with products already conformant to Electronic Prescribing – Conformance Profile v3.0.1 or EP CPv3.0.2 have until **30 November 2026** to complete uplift and delta testing for the eRx RESTful API.
- By **31 March 2027**, software developers must transition their full customer base to Electronic Prescribing – Conformance Profile v3.0.1 or EP CPv3.0.2 conformant products using the eRx RESTful API.

After 31 March 2027, all legacy connections using EP CPv2.3 Conformance IDs and those operating on the eRx adapter will be disabled. Products that do not meet these requirements risk removal from the Electronic Prescribing Conformance Register, which would prevent end users from issuing or dispensing electronic prescriptions.

I recognise that there are a number of vendors who have not yet commenced the process to seek conformance assessment against EP CPv3.0.1. To assist with an expected increase in submissions, the Agency has worked with our colleagues in the National Prescription Delivery Service to proactively manage the pipeline of assessments. Further, the Agency is supplementing the conformance assessment team within the National Prescription Delivery Service to provide an increased capacity to quickly assess conformance submissions. Assessment of products for Healthcare Identifiers conformance by the Agency has been modified to prioritise any assessments related to electronic prescribing.

Australian Digital Health Agency ABN 84 425 496 912
GPO Box 9942, Canberra ACT 2601
Phone 1300 901 001
www.digitalhealth.gov.au

To support timely assessment ahead of the deadlines:

- Vendors requiring uplift to EP CPv3.0.1 should submit their self-assessment and supporting evidence to the National Prescription Delivery Service (ePrescribing@erx.com.au) by 31 July 2026.
- If your product has not yet achieved Healthcare Identifiers (HI) conformance for use cases UC010, UC015, UC330 and/or UC325, please urgently email help@digitalhealth.gov.au to arrange assessment. Conformance to the additional HI use cases is a mandatory prerequisite before commencing EP conformance testing. Adequate time should also be factored in for testing and remediation. Delay may impact your ability to meet the required timeframes.
- Vendors requiring uplift to RESTful API should submit their self-assessment and supporting evidence to the Agency (help@digitalhealth.gov.au) by 31 July 2026. Please reach out to the Agency if you require the delta test cases for RESTful API uplift.

Submissions received by this date will be prioritised to guarantee access to an assessment slot ahead of the deadline with a commitment that subject to vendors submitting robust evidence and their systems being ready for testing, the Agency will work with the National Prescription Delivery Service team to ensure that these assessments are finalised prior to 30 September 2026.

Submissions received after 31 July 2026 will be assessed in accordance with the normal arrangements (plus the additional resourcing and other measures outlined above), however we cannot guarantee that late submissions will be assessed and determined prior to 30 September 2026.

We strongly encourage all vendors to submit evidence as early as possible, as demand for assessment and testing typically increases significantly closer to key dates. Late engagement may result in delays to assessment scheduling, reduced time for remediation, and an increased risk of non-compliance. The assessments may be prioritised as needed in order of Dispensing, Prescribing and Mobile Channels.

The Agency recognises the significant effort required to uplift systems and appreciates the continued collaboration of the software industry in supporting the national implementation of electronic prescribing. While we remain committed to assisting vendors through this transition, it is critical that organisations take immediate action to meet the September deadline. Failure to do so will have direct impacts on system availability and your customers' ability to issue and dispense electronic prescriptions.

Yours sincerely



Peter O'Halloran
Chief Digital Officer

25 June 2026